AHA again urges HHS to protect 340B program from drug companies’ actions

Sep 08, 2020 - 02:39 PM
AHA-OIG-letter

The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals. 

While the Health Resources and Services Administration, which oversees the 340B program, is investigating these activities, AHA urged HHS to take “swift and decisive action to halt these pernicious tactics” to prevent other manufacturers from following suit.

“The drug companies are attempting to exploit for their financial benefit the current COVID-19 health care crisis,” AHA said. “As you are aware, hospitals throughout the nation are under severe stress by the need to prepare for, and/or care for, COVID-19 patients, while coping with the financial damages inflicted by the virus. Therefore, we urge you to act immediately against any drug manufacturer employing these pernicious tactics to ensure that 340B drugs are available and accessible to vulnerable communities.” Read the full letter here.

The AHA has engaged in numerous efforts urging the drug companies to cease these activities and have HHS take action to protect 340B hospitals. See the previous letters the AHA has sent on the issue:

Related News Articles

Headline
Appeals court upholds Louisiana 340B contract pharmacy law
The 5th U.S. Circuit Court of Appeals Feb. 9 affirmed a district court ruling upholding Louisiana’s 340B contract pharmacy law. The state law prohibits…
Headline
HHS says it will scrap current 340B Rebate Model Program
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…
Headline
AHA blog: 340B is a solution, not a threat to health care affordability
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and…
Blog
340B is a Solution, not a Threat to Addressing Health Care Affordability in the U.S.
Public
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing…
Headline
AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy from going into effect 
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and Company policy from taking effect…
Headline
Government drops appeal of preliminary injunction order in AHA 340B lawsuit on rebate model program
The federal government has dropped its appeal of a preliminary injunction blocking implementation of the Department of Health and Human Services’ 340B Rebate…